Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Pediatría
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio


ENVÍO DE ARTÍCULOS






>Revistas >Revista Mexicana de Pediatría >Año 2016, No. 4


Zurita-Cruz JN
Pubertad precoz central
Rev Mex Pediatr 2016; 83 (4)

Idioma: Español
Referencias bibliográficas: 58
Paginas: 133-137
Archivo PDF: 207.50 Kb.


Texto completo




RESUMEN

La pubertad precoz se define como el desarrollo de las características sexuales antes de los nueve años de edad en los varones y de los ocho en las niñas. La pubertad precoz central (PPC) se debe a una activación prematura del eje hipotálamo-hipófisis-gónada. Es más frecuente que se presente en el sexo femenino y que sea de etiología idiopática. Los datos clínicos, además de la presencia de características sexuales secundarias, son la edad ósea adelantada y una velocidad de crecimiento acelerada. El tratamiento de primera línea son los análogos de la hormona liberadora de gonadotropinas (aGnRH). Se sugiere realizar la suspensión del tratamiento cuando las niñas alcanzan una edad ósea de 12 años y los varones de 14. El inicio del tratamiento antes de los seis años de edad es un factor de buen pronóstico para la estatura adulta final. No existen suficientes estudios para evaluar a largo plazo el desarrollo de síndrome de ovario poliquístico y factores cardiometabólicos en etapa adulta en las mujeres con el antecedente de PPC. El pediatra debe realizar una revisión completa del paciente pediátrico al realizar el seguimiento de crecimiento y desarrollo, donde incluya revisión del estadio de Tanner.


Palabras clave: Pubertad precoz central.


REFERENCIAS

  1. Barrón C, Pérez-Pasten E. Crecimiento y desarrollo II. En: Games J, Palacios JL. Introducción a la Pediatría. 6.a ed. México: Méndez Editores; 2003. pp. 49-73.

  2. Wakabayashi Y, Nakada T, Murata K, Ohkura S, Mogi K, Navarro V et al. Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. J Neurosci. 2010; 30: 3124-3132.

  3. Teresawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev. 2001; 22: 111-151.

  4. Donato J Jr, Cravo R, Frazao R, Gautron L, Scott M, Lachey J et al. Leptin’s effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons. J Clin Invest. 2011; 121: 355-368.

  5. Suris J, Michaud P, Viner R. The adolescent with a chronic condition. Part I: developmental issues. Arch Dis Child. 2004; 89: 928-942.

  6. Rosenfield R, Lipton R, Drum M. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics. 2009; 123(1): 84-88.

  7. Shankar R, Pescovitz O. Precocious puberty. Adv Endocrinol Metab. 1995; 6: 55-89.

  8. Kaplowitz P, Oberfield S. The Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Pediatrics. 1999; 104: 936-941.

  9. Sorensen K, Mouritsen A, Aksglaede L, Hagen C, Mogensen S, Juul A. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr. 2012; 77: 137-145.

  10. González E. For puberty that comes too soon, new treatment highly effective. JAMA. 1982; 248: 1149-1152.

  11. Cutler GB. Precocious puberty. In: Hurst JW, ed. Medicine for the practicing physician. 2nd ed. Woburn, MA: Butterworth; 1988. pp. 526-530.

  12. Grumbach M, Styne D. Puberty: ontogeneity, neuroendocrinology, physiology and disorders. In: Wilson J, Foster D, Kronenberg H, Larsen P, eds. William’s textbook of endocrinology. 9th ed. Philadelphia: WB Saunders Co. Publishing; 1998. pp. 1509-1625.

  13. Carel J, Lahlou N, Roger M, Chaussain J. Precocious puberty and statural growth. Hum Reprod Update. 2004; 10(2): 135-147.

  14. Weichold K, Silbereisen R, Schmitt-Rodermund E. Short- and long-term consequences of early versus late physical maturation in adolescents. In: Hayward C, ed. Puberty and psychopathology. Cambridge, MA: Cambridge University Press; 2003. pp. 241-276.

  15. Downing J, Bellis M. Early pubertal onset and its relationship with sexual risk taking, substance use and anti-social behaviour: a preliminary cross-sectional study. BMC Public Health. 2009; 3: 446.

  16. Kletter G, Kelch R. Clinical review 60: effects of gonadotrophin releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. 1994; 79: 331-334.

  17. Bar A, Linder B, Sobel E, Saenger P, DiMartino-Nardi J. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J Pediatr. 1995; 126: 955-958.

  18. Carel J, Eugster E, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123: e752-e762.

  19. Auchus R, Rainey W. Adrenarche-physiology, biochemistry and human disease. Clin Endocrinol. 2004; 60: 288-296.

  20. Idkowiak J, Lavery G, Dhir V, Barrett TG, Stewart PM, Krone N et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol. 2011; 165: 189-207.

  21. Herman-Giddens M, Slora E, Wasserman R, Wasserman R, Bourdony C, Bhapkar M et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics. 1997; 99: 505-512.

  22. Berberoğlu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management. J Clin Res Pediatr Endocrinol. 2009; 1(4): 164-174.

  23. Auchus R. The physiology and biochemistry of adrenarche. Endocr Dev. 2011; 20: 20-27.

  24. Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006; 117: 117-121.

  25. Ibañez L, Potau N, Zampolli M, Rique S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab. 1997; 82: 2283-2288.

  26. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger DB. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. Clin Endocrinol. 2003; 58(3): 372-379.

  27. Lee P. Central precocious puberty: an overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am. 1999; 28: 901-918.

  28. Neely E, Wilson D, Lee P, Stene M, Hintz R. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995; 127: 47-52.

  29. Brito V, Batista M, Borges M, Latronico A, Kohek M, Thirone A et al. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab. 1999; 84: 3539-3544.

  30. Kappy M, Stuart T, Perelman M. Efficacy of leuprolide therapy in children with central precocious puberty. Am J Dis Child. 1988; 142: 1061-1064.

  31. Kandemir N, Demirbilek H, Alev Ozon Z, Alikaflifo N. GnRH stimulation test in precocious puberty: single sample is adequate for diagnosis and dose adjustment. J Clin Res Ped Endocrinol. 2011; 3: 12-17.

  32. Resende E, Lara B, Reis J, Ferreira B, Pereira G, Borges M. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab. 2007; 92: 1424-1429.

  33. Roger M, Lahlou N, Chaussain J. Gonadotropin-releasing hormone testing in pediatrics. In: Ranke M, ed. Diagnostics of endocrine function in children and adolescents. Heidelberg, Germany: Johann Ambrosius Barth; 1996. pp. 346-69.

  34. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004; 6: 211-231.

  35. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux D, Cutler G Jr. Therapeutic use of pituitary desensitization with a long-acting LHrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981; 52: 370-372.

  36. Tuvemo T, Gustafsson J, Proos L. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Horm Res. 2002; 57: 27-31.

  37. Partsch C, Sippell W. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab. 22002; 16: 165-189.

  38. Chirico V, Lacquaniti A, Salpietro V, Buemi M, Salpietro C et al. Central precocious puberty: from physiopathological mechanisms to treatment. J Biol Regul Homeost Agents. 2014; 28: 367-375.

  39. Brito V, Latronico A, Arnhold I, Mendonca B. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004; 89: 4338-4342.

  40. Carel J, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. 2002; 87: 4111-4116.

  41. Fuld K, Chi C, Neely E. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011; 159: 982-987.

  42. Lee P, Klein K, Mauras N, Neely E, Bloch C, Larsen L et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012; 97: 1572-1580.

  43. Mericq V, Lammoglia J, Unanue N, Villaroel C, Hernández M, Ávila A et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol (Oxf). 2009; 71: 686-690.

  44. Badaru A, Wilson D, Bachrach L, Fechner P, Gandrud L, Durham E et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006; 91: 1862-1867.

  45. Carel J, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J et al. Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab. 1999; 84: 1973-1978.

  46. Dixon J, Ahmed S. Precocious puberty. Paediatr Child Health. 2007; 17: 343-348.

  47. Klein K, Barnes K, Jones J, Feuillan P, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001; 86: 4711-4716.

  48. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino A et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999; 141: 140-144.

  49. Mul D, Bertelloni S, Carel J, Saggese G, Chaussain J, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res. 2002; 58: 1-7.

  50. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res. 1997; 47: 54-61.

  51. Wagner IV, Sabin MA, Pfaffle RW, Hiemisch A, Sergeyev E, Korner A et al. Effects of obesity on human sexual development. Nature reviews. Endocrinology. 2012; 8: 246-254.

  52. Zurita-Cruz JN, Díaz-Rodríguez I, Nishimura-Meguro E, Villasis-Keever MA, Rivera-Hernández A et al. Change in body mass index among girls with precocious puberty under treatment. Arch Argent Pediatr. 2016; 114: 143-145.

  53. Giabicani E, Allali S, Durand D, Sommet J, Couto-Silva A et al. Presentation of 493 consecutive girls with idiopathic central precocious puberty: a single-center study. PLoS ONE. 2013; 8: e70931.

  54. Lazar L, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014; 80: 570-576.

  55. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf). 2004; 61: 626-634.

  56. Heger S, Müller M, Ranke M, Schwarz H, Waldhauser F et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006; 254-255: 217-220.

  57. Cassio A, Bal M, Orsini L, Balsamo A, Sansavini S et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr. 2006; 149: 532-536.

  58. Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril. 2010; 93: 1185-1191.



>Revistas >Revista Mexicana de Pediatría >Año2016, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019